Coherus Will Launch US Lucentis Biosimilar By 2021
Deal With Bioeq Pulls Forward Ranibizumab Launch By Two Years
Buoyed by the success of its Udenyca pegfilgrastim biosimilar, Coherus has struck a deal with Bioeq to acquire commercialization rights to its biosimilar version of Lucentis (ranibizumab) in the US, eyeing a launch date of 2021.
You may also be interested in...
Coherus Awaits August 2022 Date As FDA Accepts Ranibizumab Biosimilar
The US FDA has accepted for review the CHS-201 Lucentis biosimilar product developed by Formycon/Bioeq that is to be sold in the US by Coherus BioSciences, shortly after approving the first ranibizumab biosimilar to treat wet age-related macular degeneration.
Formycon Delay Pushes Back Coherus’ Ranibizumab
Formycon and Bioeq’s US filing for a biosimilar ranibizumab rival to Lucentis has been delayed after the FDA requested further data following a manufacturing change. Rights to the biosimilar have been licensed exclusively to Coherus in the US.
Coherus Acquires Bevacizumab Rights From Innovent
Coherus BioSciences has struck a deal with China’s Innovent Biologics that gives it US and Canadian rights to a bevacizumab biosimilar version of Avastin as well as an option to market Innovent’s rituximab rival to Rituxan in the US and Canada.